Tirzepatide CV biomarkers in SURMOUNT-1

A post hoc analysis of the SURMOUNT-1 trial, published in the Journal of the American College of Cardiology on 3 June 2026, measured 72 weeks of changes in cardiovascular risk biomarkers among adults with obesity taking tirzepatide^[1]. The analysis found broad, dose-dependent improvements across inflammatory, metabolic, endothelial, and thrombotic markers at the 15 mg dose. The findings add mechanistic colour to the weight-loss numbers already established in the original trial.

What the analysis measured

Naveed Sattar (University of Glasgow), Paul Ridker (Harvard/Brigham and Women's Hospital), and colleagues at Eli Lilly selected 392 participants from the original SURMOUNT-1 cohort (100 per group: placebo, 5 mg, 10 mg, and 15 mg) and tracked a panel of cardiovascular biomarkers at baseline, 24 weeks, and 72 weeks^[1]. The parent trial randomised 2,539 adults with obesity but without diabetes to once-weekly tirzepatide or placebo, all receiving lifestyle counselling^[2].

The numbers at 72 weeks

Inflammation: high-sensitivity C-reactive protein fell 36.9% to 54.6% across the tirzepatide doses, and interleukin-6 fell 25.4% to 30.2%. Metabolic and adiposity markers shifted in the expected direction: leptin dropped 44.4% to 61.4%, insulin resistance (measured by HOMA-IR) improved 26.4% to 39.1%, and adiponectin rose 21.1% to 47.7%. For endothelial function, E-selectin fell 12.6% to 26.4%, and soluble ICAM-1 fell 9.7% to 11.1%. Plasminogen activator inhibitor-1 (PAI-1), a thrombosis marker, dropped 35.6% to 44.3%^[1].

The pattern was dose-dependent for most markers. Higher doses produced larger reductions across nearly every biomarker in the panel. This is consistent with what clinicians would expect from a treatment that produces 15% to 21% body-weight loss over 72 weeks.

Two markers stand out for context. The CRP reductions (up to 54.6% on the 15 mg dose) are large by the standards of obesity interventions and overlap with the magnitude seen in statin trials, though the mechanism is entirely different. The PAI-1 drop (up to 44.3%) is relevant because elevated PAI-1 is associated with impaired fibrinolysis and higher thrombotic risk in obesity. Both markers track pathways that cardiologists already monitor when assessing cardiovascular risk in patients with metabolic syndrome.

Whether these biomarker shifts are entirely explained by the weight loss itself, or whether tirzepatide has direct vascular or anti-inflammatory effects beyond weight reduction, is not answered by this study design. That distinction matters clinically because it determines whether the cardiovascular benefit would persist if a patient regained weight after stopping treatment, as SURMOUNT-4 showed happens in most cases.

What this does not tell us

Biomarker improvement is not the same as event reduction. High-sensitivity CRP falling by half does not mean heart attacks fall by half. The analysis is a post hoc substudy of 392 people from a trial designed to measure weight, not cardiovascular events. The authors themselves frame the work as hypothesis-generating. For hard outcomes, the closest existing data is the SUMMIT trial in heart failure with preserved ejection fraction and obesity, which reported a 38% reduction in cardiovascular death or worsening heart-failure events on tirzepatide^[3]. A dedicated MACE outcomes trial in the broader obesity-without-diabetes population, matching what SELECT did for semaglutide, has not yet read out.

The sample size (n=392) also limits subgroup analysis. The trial enrolled adults without diabetes, so the results do not apply directly to people taking tirzepatide for type-2 diabetes, who carry a different baseline cardiovascular risk profile. And because SURMOUNT-1 excluded participants with recent cardiovascular events, the population studied here is lower-risk than the one enrolled in SELECT (the semaglutide cardiovascular outcomes trial), which required established cardiovascular disease at entry.

Why this matters for the tirzepatide picture

Tirzepatide already has the largest mean weight-loss figures of any approved obesity medicine (20.9% at 72 weeks on 15 mg in SURMOUNT-1) and a head-to-head advantage over semaglutide in SURMOUNT-5. What it does not yet have is a labelled cardiovascular risk-reduction claim. This biomarker analysis does not deliver that claim, but it maps the pathways that a future outcomes trial would need to confirm: less inflammation, less insulin resistance, less endothelial activation, less prothrombotic signalling^[1].

For readers tracking tirzepatide's regulatory and clinical trajectory, the full tirzepatide page covers the trial programme, per-country regulation status, and the open questions around long-term use. When a dedicated MACE outcomes trial reads out, this page will update with the hard-endpoint data that the biomarker analysis points toward.